Intravenous Immunoglobulins Market to Exhibit 6.2% CAGR, Among Indications, Primary Immunodeficiency Segment Forecast to Emerge Dominant

In the Intravenous Immunoglobulin Market, primary immunodeficiency segment holds the highest share in terms of indication. Fortune Business Insights has published a report, titled “Intravenous Immunoglobulins: Global Market Analysis, Insights and Forecast, 2018-2025,” which offers comprehensive overview of the market. According to the report, the global market was valued at US$ 9,787.6 Mn in 2017. By the end of 2025, the market is foreseen to progress at a CAGR of 6.2% and reach US$ 15,789.1 Mn. 

On the basis of indication, primary immunodeficiency segment held 28.6% in 2017. The segment is further expected to show impressive growth during the forecast period 2018-2025. Owing to the rising prevalence of primary immunodeficiency, the market is likely to witness high demand for immunoglobulins. Moreover, increasing focus on the diagnosis of primary immunodeficiency is anticipated to enable growth in the market. Besides this, in several cases the patient is unable to perform self-intervention this is anticipated to encourage the adoption of intravenous immunoglobulin. The chronic inflammatory demyelinating polyneuropathy (CIDP) segment is estimated to expand at a slower CAGR during the forecast period. This is attributed to the comparatively lower prevalence of chronic inflammatory demyelinating polyneuropathy. 

Increasing Disposable Income to Encourage Adoption of Immunoglobulin 

“Greater awareness regarding immunodeficiencies and advancements in the immunoglobulins’ efficiency in their treatment is anticipated. This is likely to boost the adoption of immunodeficiency diagnosis and boost the growth rate in the market.” Said a lead analyst at Fortune Business Insights. 

Increasing disposable income and increasing cases of immunodeficiency are a few factors anticipated to drive the global intravenous immunoglobulin market. The increasing number of patients in the hospital and specialty clinic is further fueling the demand for intravenous immunoglobulin. Additionally, the proven efficiency of immunoglobulins as an effective treatment option for various immune diseases is likely to propel growth in the market. 

On the flip side, side-effects and high cost associated with the immunoglobulin is a major factor that may hamper the growth in the market during the forecast period. 

Japan’s Huge Investment in Advanced Immunoglobulins to Enable Growth 

In the Asia Pacific intravenous immunoglobulin market, Japan holds a major share in the immunoglobulins market due to the adoption of advanced intravenous immunoglobulins. This is further expected to enable growth in the global market. In terms of indication, primary immunodeficiency is leading in the Asia Pacific market Besides this, in 2017 the North America intravenous immunoglobulin market was valued at US$ 5,587.4 Mn. North America is projected to emerge dominant in the global market over the forecast period.

Grifols, S.A., was the leading player in the global market in 2017. Moreover, in Europe and North America market Grifols, S.A. holds the dominant share. Owing to the organization’s product portfolio, Grifols, S.A. has gained momentum over the years. Other players operating in the global intravenous immunoglobulin market are CSL Behring, Grifols, S.A., Kedrion S.p.A, Octapharma, Bio Products Laboratory Ltd., Biotest AG, China Biologic Products Holdings, Inc., LFB SA, and Shanghai RAAS Blood Products Co., Ltd. 

Browse Complete Report Details @ https://www.fortunebusinessinsights.com/industry-reports/intravenous-immunoglobulins-market-100593

Key segments within the market